The only difference was in the higher mutation burden in their ETP ALL patients and adverse prognostic impact of TP53 mutation in comparison to our study in which both ETP and Non-ETP patients had equivalent mutational burden (Table 2), and prognostic significance of TP53 mutation could not be ascertained due to paucity of TP53 mutations [13, 14]. Here, TP53 is linked to acute lymphoblastic leukemia.